<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965820</url>
  </required_header>
  <id_info>
    <org_study_id>LCO115-P001</org_study_id>
    <nct_id>NCT02965820</nct_id>
  </id_info>
  <brief_title>OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers</brief_title>
  <official_title>Clinical Study of OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate OPTI-FREE® PureMoist® (OFPM) compared to
      non-HYDRAGLYDE® multipurpose contact lens solutions in presbyopes currently wearing soft
      contact lenses and experiencing symptoms of dryness.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Anticipated">April 3, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) score at Day 30</measure>
    <time_frame>Day 30, each product</time_frame>
    <description>CLDEQ-8 score (assessment of contact lens discomfort) as obtained by adding the numerical responses to each of 8 items (range 0 to 37).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>OFPM, then HMPS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by participant's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with participant's habitual contact lenses for approximately 30 cleaning and disinfection cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMPS, then OFPM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participant's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual contact lenses for approximately 30 cleaning and disinfection cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Opti-Free® PureMoist® contact lens solution</intervention_name>
    <arm_group_label>OFPM, then HMPS</arm_group_label>
    <arm_group_label>HMPS, then OFPM</arm_group_label>
    <other_name>OPTI-FREE® PureMoist®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Habitual Multi-Purpose Contact Lens Solution</intervention_name>
    <arm_group_label>OFPM, then HMPS</arm_group_label>
    <arm_group_label>HMPS, then OFPM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Habitual Contact Lenses</intervention_name>
    <description>Participant's habitual contact lens brand worn in a daily wear modality for 30 days.</description>
    <arm_group_label>OFPM, then HMPS</arm_group_label>
    <arm_group_label>HMPS, then OFPM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must sign an informed consent document;

          -  Current adapted two-week/monthly replacement soft contact lens wearers (at least 2
             months) with symptoms of contact lens induced dryness;

          -  Near spectacle add of +0.50 or greater;

          -  Best corrected visual acuity (BCVA) to 20/30 or better in each eye at distance;

          -  Willing to wear lenses for a minimum of 5 days per week, 6 hours per day, and attend
             all study visits;

          -  Currently using a non-Alcon multi-purpose solution to care for lenses (at least 2
             months);

          -  Use of digital devices (eg, smart phone, tablet, laptop computer, or desktop
             computer) for 20 consecutive minutes at least twice a week and willing to continue
             the same pattern for the duration of the study;

          -  Other protocol-specific inclusion criteria may apply.

        Exclusion Criteria:

          -  Extended wear contact lens wearer (sleeps in lenses 1 or more nights per week);

          -  Any anterior segment infection, inflammation, disease, or abnormality that
             contraindicates contact lens wear as determined by the investigator;

          -  Any use of systemic or ocular medications for which contact lens wear could be
             contraindicated, as determined by the investigator, including use of any topical
             ocular medications that would require instillation during contact lens wear;

          -  Monocular (only 1 eye with functional vision) or fit with only 1 lens;

          -  Known sensitivity to any ingredients in OFPM;

          -  Prior refractive surgery;

          -  History of herpetic keratitis, ocular surgery, or irregular cornea;

          -  Pathological dry eye that precludes contact lens wear;

          -  Use of mechanical eyelid therapy or eyelid scrubs within 14 days before Visit 1 and
             not willing to discontinue during the study;

          -  Participation in any clinical study within 30 days of Visit 1;

          -  Currently using or have not discontinued Restasis®, Xiidra® or a topical steroid
             within the past 7 days;

          -  Other protocol-specific exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Project Manager, CPM</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>November 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact lens induced dryness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Contact Lens Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
